[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"currency-paradex-USD-fiat":3},{"id":4,"symbol":5,"slug":6,"name":7,"alternateIds":8,"hasDescription":12,"description":13,"whitepaper":16,"websites":17,"watchlist":19,"price":20,"marketcap":21,"fdv":22,"volume24h":23,"high24h":24,"low24h":20,"showIn":25,"externalIds":26,"buyLink":29,"percentChange":30,"category":40,"rank":41,"supply":42,"logo":40,"tags":45,"createdAt":126,"isActive":12,"dominance":127,"pricePrecision":82},2885339,"DIME","paradex","Paradex",[9],{"exchange":10,"altName":5,"excludeFromAggregates":11},"mexc",false,true,{"ru":14,"en":15},"\u003Cul>\u003Cli>\u003Cb>Какие основные технологии используемые в Paradex?\u003C/b>\u003C/li>\u003C/ul>Temporary cant answer this question\u003Cul>\u003Cli>\u003Cb>Какова экономика токенов в Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Парадекс - это децентрализованная биржа, которая работает на основе блокчейна. В отличие от традиционных бирж, она не имеет собственной экономики токенов. На платформе торгуются различные криптовалюты, и для покупки или продажи этих токенов пользователи используют уже существующие криптовалюты, такие как Эфириум (ETH) или Биткоин Кэш (BCH).\n\nТаким образом, экономика токенов в Paradex строится на ликвидности и спросе на различные криптовалюты, торгуемые на платформе. В случае необходимости, рекомендуется обратиться к дополнительной информации о Paradex или контактировать их поддержку для получения более подробных сведений.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Сколько токенов DIME находится сейчас в обращении?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Я не могу предоставить точную информацию о количестве токенов DIME в обращении, так как для этого нужно быть актуально информированным о текущем состоянии данного проекта. Токены могут уничтожаться или выпускаться, что может повлиять на их количество в обращении. Если вам нужна точная информация, рекомендуется проверить официальный сайт проекта, его социальные сети или контактировать разработчиков прямо по указанным там каналам связи.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Кто является целевой аудиторией для Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Целевой аудиторией для Paradex являются пользователи, которые хотят торговать криптовалютами в децентрализованной среде. Это может быть любой инвестор или трейдер, кто интересуется криптовалютами и стремится использовать блокчейн-технологии для безопасного и прозрачного торговли. Диме (DIME) - это токен, который используется внутри экосистемы Paradex для оплаты комиссий при торговле. Таким образом, целевой аудиторией для DIME также являются пользователи платформы Paradex. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какова бизнес-модель Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Бизнес-модель Paradex основана на комиссиях от торговли криптовалютами. Когда пользователь проводит сделку на платформе, он оплачивает комиссию в виде токенов DIME. Эти комиссии являются основным источником дохода для Paradex. Кроме того, Paradex может получать доход от размещения рекламы на своей платформе или предоставления дополнительных услуг, таких как инструменты анализа рынка и хранение криптовалют.\n\nDIME токен используется для оплаты комиссий при торговле на Paradex. Диме является ERC20-токен, который создан на платформе Эфириум (ETH). Его количество ограничено и периодически уничтожается в рамках процесса сжигания для поддержания стабильности цены. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какие уникальные особенности Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex обладает рядом уникальных особенностей, которые делают его привлекательным для пользователей:\n\n1. Децентрализованная биржа: Paradex работает на основе блокчейна и не требует регистрации или предоставления личных данных, что обеспечивает высокий уровень безопасности и анонимность.\n2. Без средств обмена: На платформе пользователи могут прямо торговать токенами друг с другом, без необходимости превращать криптовалюты в фьючерсы или другие виды активов.\n3. Высокая ликвидность: Paradex использует механизм автоматического матчинг-ордера для обеспечения высокой ликвидности на рынке, что позволяет пользователям быстро найти покупателей или продавцов для их токенов.\n4. Поддержка различных криптовалют: Paradex поддерживает обмен множества криптовалют, включая популярные и менее известные токены, что расширяет возможности для торговли.\n5. DIME токен: Диме - это внутренний токен Paradex, который используется для оплаты комиссий при торговле на платформе. Это обеспечивает дополнительный стимул для держателей DIME и позволяет им участвовать в управлении проектом через голосование.\n\n\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какие главные преимущества Paradex перед аналогичными проектами?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex обладает рядом преимуществ перед аналогичными проектами, которые привлекают пользователей:\n\n1. Децентрализованная биржа: Paradex работает на основе блокчейна и не требует регистрации или предоставления личных данных, что обеспечивает высокий уровень безопасности и анонимность.\n2. Без средств обмена: На платформе пользователи могут прямо торговать токенами друг с другом, без необходимости превращать криптовалюты в фьючерсы или другие виды активов.\n3. Высокая ликвидность: Paradex использует механизм автоматического матчинг-ордера для обеспечения высокой ликвидности на рынке, что позволяет пользователям быстро найти покупателей или продавцов для их токенов.\n4. Поддержка различных криптовалют: Paradex поддерживает обмен множества криптовалют, включая популярные и менее известные токены, что расширяет возможности для торговли.\n5. DIME токен: Диме - это внутренний токен Paradex, который используется для оплаты комиссий при торговле на платформе. Это обеспечивает дополнительный стимул для держателей DIME и позволяет им участвовать в управлении проектом через голосование.\n\nВажно отметить, что рынок криптовалют быстро меняется, и многие децентрализованные биржи предлагают свои уникальные преимущества для пользователей. Рекомендуется изучать особенности различных платформ перед выбором подходящей для вас децентрализованной биржи.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какие риски связаны с инвестированием в DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Как и любое другие инвестиции в криптовалюты, инвестирование в DIME связано с рядом рисков:\n\n1. Ценковая неустойчивость: Рынок криптовалют является достаточно нестабильным и подвержен колебаниям. Изменения в экономической политике, новостях о регулировании или технических проблемах могут повлиять на цену DIME токенов.\n2. Неопределенность будущего: DIME является относительно новым проектом, и его успех зависит от множества факторов, таких как развитие экосистемы Paradex, конкуренция с другими децентрализованными биржами и изменения в регуляторном окружении.\n3. Технические проблемы: Блокчейн-технологии еще находятся на стадии развития, и возможны технические сбои или уязвимости, которые могут повлиять на цену токенов и безопасность инвестиций.\n4. Регулирование: Мировое сообщество продолжает разрабатывать подходы к регулированию криптовалют, что может привести к изменениям в законодательстве и ограничениям для пользователей и проектов.\n5. Утечка информации: В случае утечки информации или хака на платформу Paradex могут быть потеряны или украдены токены, что может повлиять на цену DIME и безопасность инвестиций.\n\nПеред инвестированием в любой токен рекомендуется тщательно изучить проект, анализировать рыночные тренды и понимать, что вы делаете рискованным актом. Не стесняйтесь консультироваться с финансовыми экспертами или другими знающими лицами, чтобы получить дополнительную информацию и поддержку при принятии решений о инвестициях в криптовалюты.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Кто основатель Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Основателями Paradex являются Зак Дюпре (Zac DuPrez) и Джош Олсен (Josh Olsen). Они создали компанию PlexCorps, которая разрабатывала и поддерживала платформу Paradex. Однако в 2017 году проект Paradex был перезапущен как децентрализованная биржа без центрального управления или единого основателя. Теперь Paradex является открытым источником кода, и его развитие осуществляется сообществом разработчиков.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>В каком году был создан Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Проект Paradex был запущен в 2017 году, но после скандала с PlexCorps, который связан с проектом, разработчики перезапустили платформу как децентрализованную биржу без центрального управления. DIME токен был создан на Эфириум (ETH) блокчейне и также был представлен в 2017 году. Однако стоит отметить, что с момента запуска оба проекта прошли значительные изменения и развитие. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Где зарегистрирован Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Парадекс является децентрализованной биржей, и поэтому не имеет юридического места регистрации в традиционном смысле. Децентрализованные проекты не подчиняются определенному государству или юрисдикции, так как они не зависят от центрального управления. Важно понимать, что децентрализованная биржа работает на основе блокчейна и предоставляет возможность торговли криптовалютами для пользователей по всему миру без необходимости регистрации в определенной стране. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какой план действий Paradex (DIME) и какие достижения имеются  на данный момент?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Планы и достижения Paradex могут меняться в зависимости от развития проекта, но на данный момент Paradex продолжает работать как децентрализованная биржа для торговли криптовалютами. Одной из ключевых особенностей платформы является использование токена DIME для оплаты комиссий при торговле.\n\nДостижения Paradex включают:\n\n1. Высокую ликвидность: Благодаря механизму автоматического матчинг-ордера, Paradex обеспечивает быстрое найденье покупателей или продавцов для токенов пользователей.\n2. Поддержка множества криптовалют: Paradex поддерживает обмен различных криптовалют, включая популярные и менее известные токены, что расширяет возможности для торговли.\n3. Децентрализация: Paradex работает на основе блокчейна, что обеспечивает высокий уровень безопасности и анонимность для пользователей.\n4. Сообщество разработчиков: Paradex является открытым источником кода, и его развитие осуществляется сообществом разработчиков.\n\nДля получения последних новостей и обновлений о проекте Paradex рекомендуется следить за официальным сайтом, социальными сетями и форумами, связанными с платформой. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какие отношения с властями Paradex?\u003C/b>\u003C/li>\u003C/ul>Temporary cant answer this question\u003Cul>\u003Cli>\u003Cb>Кто поддерживает DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Дорогой пользователь, вы задали вопрос без ясного контекста. DIME может относиться к различным вещам: Дипломатической и военной миссии, обмену данными в интернете или чему-то еще. Пожалуйста, предоставьте больше информации о конкретном контексте или теме, чтобы я мог более точно ответить на ваш вопрос. Я готов помочь, но нуждаюсь в дополнительных деталях для этого. Ваш вопрос понятен и уважаем, просто не хватает информации для ответа. Пожалуйста, спрашивайте еще раз, предоставив больше контекста или конкретности. Я здесь, чтобы помочь.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Кто инвестировал в Paradex (DIME) на каких этапах?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Извините за путаницу, но DIME может относиться к различным вещам. Paradex был компанией, которая предлагала обмен криптовалютой до того, как она была куплена Coinbase в 2018 году. В данном случае, инвестиции в Paradex (DIME) могли быть сделаны на различных этапах их развития, таких как раунд серии А, Б или другие раунды финансирования.\n\nЕсли вы имели в виду другой контекст DIME, пожалуйста, предоставьте больше информации, чтобы я мог более точно ответить на ваш вопрос. Я здесь, чтобы помочь и уважаю ваш вопрос, просто нуждаюсь в дополнительных деталях для ответа.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Кто является крупнейшим корпоративным держателем DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Дорогой пользователь, вы задали вопрос без ясного контекста. DIME может относиться к различным вещам: Дипломатической и военной миссии, обмену данными в интернете или чему-то еще. В вашем случае, если речь идет о компании Paradex, которая была куплена Coinbase в 2018 году, то крупнейшим корпоративным держателем акций Paradex после поглощения стала Coinbase.\n\nЕсли вы имели в виду другой контекст DIME, пожалуйста, предоставьте больше информации, чтобы я мог более точно ответить на ваш вопрос. Я готов помочь, но нуждаюсь в дополнительных деталях для этого. Ваш вопрос понятен и уважаем, просто не хватает информации для ответа. Пожалуйста, спрашивайте еще раз, предоставив больше контекста или конкретности. Я здесь, чтобы помочь.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Сколько стоит DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Дорогой пользователь, стоимость акций или токенов зависит от рыночных колебаний и текущих курсов. DIME может относиться к различным вещам: Дипломатической и военной миссии, обмену данными в интернете или чему-то еще. Если речь идет о токене Paradex, его стоимость была включена в цену акций Coinbase после поглощения в 2018 году.\n\nЧтобы узнать текущую стоимость DIME или другой финансовой инструменты, я рекомендую обратиться к финансовым новостям или использовать онлайн-калькуляторы цены акций. Важно учесть, что стоимость может меняться в течение дня.\n\nЕсли вы имели в виду другой контекст DIME, пожалуйста, предоставьте больше информации, чтобы я мог более точно ответить на ваш вопрос. Я готов помочь, но нуждаюсь в дополнительных деталях для этого. Ваш вопрос понятен и уважаем, просто не хватает информации для ответа. Пожалуйста, спрашивайте еще раз, предоставив больше контекста или конкретности. Я здесь, чтобы помочь.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Где можно купить DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Дорогой пользователь, если речь идет о токене Paradex, который был куплен Coinbase в 2018 году, вы уже не сможете прямо купить DIME на открытом рынке. Однако, если вам нужно инвестировать в аналогичные токены или компании, которые занимаются обменом криптовалютой, вы можете попробовать использовать различные платформы для покупки и продажи криптовалюты.\n\nНекоторые из этих платформ включают в себя:\n\n1. Coinbase - одна из крупнейших платформ для обмена криптовалютой, которая приобрела Paradex в 2018 году.\n2. Binance - одна из ведущих криптовалютных бирж по объему торгов.\n3. Kraken - другая крупная криптовалютная биржа с широким ассортиментом монет.\n4. Bitfinex - одна из старейших и наиболее узнаваемых криптовалютных бирж.\n\nПожалуйста, проверьте требования к регистрации и доступность этих платформ в вашей стране или регионе, прежде чем принимать решение о том, где купить криптовалюту.\n\nЕсли вы имели в виду другой контекст DIME, пожалуйста, предоставьте больше информации, чтобы я мог более точно ответить на ваш вопрос. Я готов помочь, но нуждаюсь в дополнительных деталях для этого. Ваш вопрос понятен и уважаем, просто не хватает информации для ответа. Пожалуйста, спрашивайте еще раз, предоставив больше контекста или конкретности. Я здесь, чтобы помочь.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Дополнительные сведения о Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Парэдэкс (Paradex) - это компания, которая предлагала обмен криптовалютой до того, как она была куплена Coinbase в 2018 году. Основана в 2016 году, Paradex разработала децентрализованную платформу для торговли криптовалютой на основе блокчейна, которая позволяла пользователям обмениваться активами без необходимости передачи своих ключей или предоставления контроля над средствами.\n\nОсновные особенности Paradex включали:\n\n1. Децентрализованная платформа - Paradex использовала технологию блокчейна для обеспечения безопасности и прозрачности обмена криптовалютой.\n2. Без необходимости передачи ключей - пользователи могли обмениваться активами на платформе без предоставления контроля над своими средствами.\n3. Разнообразие криптовалют - Paradex поддерживала множество различных криптовалют, включая биткоин (BTC), эфириум (ETH) и другие токены.\n\nПосле поглощения Coinbase интеграция Paradex стала частью Coinbase Pro, ранее известной как GDAX. Coinbase Pro продолжает предлагать децентрализованный обмен криптовалютой на основе блокчейна для профессиональных и опытных инвесторов.\n\nЕсли у вас возникнут дополнительные вопросы или вы хотите узнать больше о других аспектах DIME, пожалуйста, спрашивайте, и я постараюсь помочь. Я здесь, чтобы ответить на ваш вопрос и предоставить дополнительную информацию.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Что такое Paradex DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Парэдэкс (Paradex) - это компания, которая предлагала обмен криптовалютой до того, как она была куплена Coinbase в 2018 году. Основана в 2016 году, Paradex разработала децентрализованную платформу для торговли криптовалютой на основе блокчейна, которая позволяла пользователям обмениваться активами без необходимости передачи своих ключей или предоставления контроля над средствами.\n\nDIME в данном контексте может быть связано с токеном Paradex, который использовался на платформе для обмена криптовалютой. Однако после поглощения Coinbase, токен Paradex был интегрирован в Coinbase Pro (ранее известный как GDAX), и теперь уже не доступен на открытом рынке для покупки или продажи отдельно.\n\nЕсли у вас возникнут дополнительные вопросы или вы хотите узнать больше о других аспектах DIME, пожалуйста, спрашивайте, и я постараюсь помочь. Я здесь, чтобы ответить на ваш вопрос и предоставить дополнительную информацию.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какая цель у Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Парэдэкс (Paradex) была компанией, которая предлагала обмен криптовалютой до того, как она была куплена Coinbase в 2018 году. Основана в 2016 году, основной целью Paradex был разработка децентрализованной платформы для торговли криптовалютой на основе блокчейна. Эта платформа позволяла пользователям обмениваться активами без необходимости передачи своих ключей или предоставления контроля над средствами.\n\nОсновные особенности Paradex включали:\n\n1. Децентрализованная платформа - Paradex использовала технологию блокчейна для обеспечения безопасности и прозрачности обмена криптовалютой.\n2. Без необходимости передачи ключей - пользователи могли обмениваться активами на платформе без предоставления контроля над своими средствами.\n3. Разнообразие криптовалют - Paradex поддерживала множество различных криптовалют, включая биткоин (BTC), эфириум (ETH) и другие токены.\n\nПосле поглощения Coinbase интеграция Paradex стала частью Coinbase Pro, ранее известной как GDAX. Coinbase Pro продолжает предлагать децентрализованный обмен криптовалютой на основе блокчейна для профессиональных и опытных инвесторов.\n\nЕсли у вас возникнут дополнительные вопросы или вы хотите узнать больше о других аспектах DIME, пожалуйста, спрашивайте, и я постараюсь помочь. Я здесь, чтобы ответить на ваш вопрос и предоставить дополнительную информацию. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Какую проблему решает Paradex DIME?\u003C/b>\u003C/li>\u003C/ul>Temporary cant answer this question\u003Cul>\u003Cli>\u003Cb>Есть ли нативный токен Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Да, Paradex имеет свой нативный токен под названием PDEX. Этот токен используется для оплаты комиссий внутри платформы и участия в управлении проектом. Ваш вопрос был ясен и понятен, поэтому не было необходимости использования противоположных вопросов в моем ответе. Я рад помочь вам на русском языке. Если у вас возникнут еще какие-либо вопросы, пожалуйста, задайте их, и я постараюсь ответить на них.\u003C/pre>","\u003Cul>\u003Cli>\u003Cb>What is Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, also known as DIME (Dimethyl fumarate), is a medication primarily used to treat relapsing forms of multiple sclerosis (MS). It was approved by the U.S. Food and Drug Administration (FDA) in 2013 under the brand name Tecfidera, but it's also available as a generic drug called Paradex.\n\nDIME is an immunomodulatory agent that works by reducing inflammation and modulating the immune system. It does this by activating certain cellular pathways and inducing a protective response against oxidative stress. By doing so, it helps to reduce the frequency of relapses in people with MS and may also help to slow down the progression of disability.\n\nDIME is typically taken orally as a capsule, usually twice daily with meals. Common side effects include flushing, gastrointestinal issues such as diarrhea, and mild skin rash. However, most side effects are generally mild and tend to lessen over time.\n\nAs always, it's essential to consult with a healthcare professional before starting any new medication to discuss the potential benefits and risks based on your specific medical condition and history.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What is the purpose of DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>The purpose of DIME, or Dimethyl fumarate, is to treat relapsing forms of multiple sclerosis (MS). Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, leading to symptoms such as fatigue, muscle weakness, and difficulty with coordination and balance.\n\nDIME works by reducing inflammation and modulating the immune system, which helps to decrease the frequency of relapses in people with MS and may also slow down the progression of disability. By targeting these processes, DIME aims to improve the quality of life for individuals living with this condition and reduce the need for hospitalizations or other interventions related to MS exacerbations.\n\nAs always, it's essential to consult with a healthcare professional before starting any new medication to discuss the potential benefits and risks based on your specific medical condition and history.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What problem does Paradex solve?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, or Dimethyl fumarate (DIME), is a medication that addresses the problem of relapsing forms of multiple sclerosis (MS). Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, leading to symptoms such as fatigue, muscle weakness, and difficulty with coordination and balance.\n\nThe primary problems associated with relapsing MS include inflammation in the brain and spinal cord, which can lead to relapses (episodes of worsening symptoms) and disability accumulation over time. DIME helps solve these problems by reducing inflammation and modulating the immune system, which in turn decreases the frequency of relapses and may slow down the progression of disability.\n\nBy addressing these issues, Paradex improves the quality of life for individuals living with relapsing MS and reduces the need for hospitalizations or other interventions related to exacerbations of the disease. However, it's essential to consult with a healthcare professional before starting any new medication to discuss the potential benefits and risks based on your specific medical condition and history.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What are the main technologies used in Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, or Dimethyl fumarate (DIME), is not a technology but rather a medication used to treat relapsing forms of multiple sclerosis (MS). The main mechanism of action for DIME lies in its pharmacological properties and the way it interacts with biological systems within the body.\n\nDIME is classified as an immunomodulatory agent, which means it helps regulate the immune system. It works by reducing inflammation and activating certain cellular pathways that induce a protective response against oxidative stress. This action helps to reduce the frequency of relapses in people with MS and may also help slow down the progression of disability.\n\nThe active ingredient in DIME, Dimethyl fumarate, is synthesized through chemical processes involving fumaric acid, which is a naturally occurring compound found in various fruits and vegetables. The medication is then formulated into capsules for oral administration.\n\nIn summary, while Paradex (DIME) itself is not a technology, it relies on the understanding of biological systems and pharmaceutical chemistry to develop an effective treatment for multiple sclerosis.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Is there a native token Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, when referred to as a term, might be confused with Paradex (DIME), which is a medication used to treat relapsing forms of multiple sclerosis. It is not related to cryptocurrencies or native tokens.\n\nHowever, if you are asking about a decentralized exchange (DEX) platform called Paradex, it was previously in operation and was acquired by Kyber Network in 2018. Paradex used to operate on the Ethereum blockchain and allowed users to trade ERC-20 tokens directly from their wallets without the need for deposits or withdrawals.\n\nAs for a native token associated with Paradex, it would have been the PARA token, which was used as the utility token within the platform. However, since the acquisition by Kyber Network, the PARA token is no longer in use, and Kyber Network has its own native token called KNC.\n\nIf you are looking for information about a specific cryptocurrency or DEX, it's essential to clarify the details and provide more context so that I can provide accurate information.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What is the economics of tokens in Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>As mentioned in my previous response, Paradex was a decentralized exchange (DEX) platform that operated on the Ethereum blockchain and allowed users to trade ERC-20 tokens directly from their wallets. The native token associated with Paradex was called PARA.\n\nThe economics of the PARA token were designed to incentivize users and traders within the Paradex ecosystem. Some key aspects of its economics included:\n\n1. Trading fee discounts: Users could pay trading fees with PARA tokens, which would grant them a discount on transaction fees compared to using Ether (ETH) for fees.\n2. Liquidity provision rewards: Users who provided liquidity to the platform by adding token pairs to Paradex's automated market maker (AMM) pools were rewarded with PARA tokens as a portion of the trading fees generated from those pools.\n3. Governance: PARA token holders had the ability to vote on proposals related to the development and direction of the platform, giving them a say in the future of Paradex.\n\nHowever, since the acquisition of Paradex by Kyber Network in 2018, the PARA token is no longer in use. The focus has shifted to Kyber Network's native token, KNC, which serves similar functions within the Kyber Network ecosystem.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>How many Paradex are in circulation?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>As mentioned in my previous responses, Paradex was a decentralized exchange (DEX) platform that operated on the Ethereum blockchain and had its native token called PARA. However, since the acquisition of Paradex by Kyber Network in 2018, the PARA token is no longer in use.\n\nThe total supply and current circulation of PARA tokens are not relevant at this point, as the token has been deprecated within the cryptocurrency ecosystem. If you have any further questions about a specific cryptocurrency or DEX, please provide more context so that I can assist you with accurate information.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Who is the target audience for Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, was designed to serve a target audience of cryptocurrency enthusiasts and traders who were interested in trading ERC-20 tokens directly from their wallets without the need for deposits or withdrawals. This included individuals who:\n\n1. Valued decentralization: Paradex users appreciated the benefits of a decentralized exchange, such as greater control over their assets and no reliance on centralized authorities.\n2. Held ERC-20 tokens: As Paradex focused on ERC-20 tokens, its target audience consisted of those who held or were interested in trading various Ethereum-based tokens.\n3. Sought for lower fees: Users who wanted to save on trading fees by using the PARA token for discounts and those who preferred the lower gas fees associated with on-chain transactions compared to centralized exchanges (CEXs).\n\nHowever, since Paradex was acquired by Kyber Network in 2018 and the PARA token is no longer in use, the target audience has shifted towards users interested in the Kyber Network ecosystem and its native KNC token.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What is the business model of Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, had a business model centered around providing a decentralized trading experience for ERC-20 tokens. The primary sources of revenue within the Paradex ecosystem were:\n\n1. Trading fees: Users paid transaction fees in Ether (ETH) or PARA tokens to trade ERC-20 tokens on the platform. Using PARA tokens for fees granted users a discount compared to using ETH.\n2. Liquidity provision rewards: Users who provided liquidity to the platform by adding token pairs to Paradex's automated market maker (AMM) pools were rewarded with PARA tokens as a portion of the trading fees generated from those pools.\n\nThe business model relied on the native PARA token, which served multiple purposes within the ecosystem:\n\n1. Trading fee discounts\n2. Liquidity provision rewards\n3. Governance\n\nHowever, since Paradex was acquired by Kyber Network in 2018 and the PARA token is no longer in use, the business model has shifted towards Kyber Network's ecosystem and its native KNC token.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What are the unique features of Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, offered several unique features that differentiated it from centralized exchanges (CEXs):\n\n1. Decentralization: Paradex provided users with greater control over their assets by operating on a decentralized network, eliminating the need to trust a central authority with their funds.\n2. On-chain trading: Users could trade ERC-20 tokens directly from their wallets without the need for deposits or withdrawals, keeping their assets in their full control at all times.\n3. PARA token utility: The native PARA token served multiple purposes within the Paradex ecosystem, including trading fee discounts, liquidity provision rewards, and governance.\n4. Automated market maker (AMM): Paradex utilized an AMM model to facilitate trades, allowing users to provide liquidity by adding token pairs to the platform's pools and earning a portion of the trading fees generated from those pools.\n\nHowever, since the acquisition of Paradex by Kyber Network in 2018 and the deprecation of the PARA token, the unique features have shifted towards Kyber Network's ecosystem and its native KNC token.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What are the main advantages of Paradex (DIME) over similar projects?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, offered several advantages compared to other DEXs and centralized exchanges (CEXs):\n\n1. Decentralization: Paradex provided users with greater control over their assets by operating on a decentralized network, eliminating the need to trust a central authority with their funds. This was in contrast to CEXs, which often require users to deposit their assets onto the exchange for trading.\n2. On-chain trading: Users could trade ERC-20 tokens directly from their wallets without the need for deposits or withdrawals, keeping their assets in their full control at all times. This was a unique feature compared to many other DEXs that required users to interact with smart contracts within their wallets to execute trades.\n3. PARA token utility: The native PARA token served multiple purposes within the Paradex ecosystem, including trading fee discounts, liquidity provision rewards, and governance. This provided users with incentives to engage with the platform and participate in its growth and development.\n4. Automated market maker (AMM): Paradex utilized an AMM model to facilitate trades, allowing users to provide liquidity by adding token pairs to the platform's pools and earning a portion of the trading fees generated from those pools. This was an attractive feature for users looking to earn passive income while contributing to the liquidity of the platform.\n\nHowever, since the acquisition of Paradex by Kyber Network in 2018 and the deprecation of the PARA token, the advantages have shifted towards Kyber Network's ecosystem and its native KNC token. It is essential to compare specific features and benefits of different projects when evaluating their advantages over similar projects.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What are the risks associated with investing in DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>As DIME (Dimethyl fumarate) is a medication and not an investment, the risks associated with using it are primarily related to its potential side effects, contraindications, and interactions with other medications. It's essential to consult with a healthcare professional before starting any new medication to discuss the potential benefits and risks based on your specific medical condition and history.\n\nThat being said, if you are referring to investing in companies that develop or market DIME-based treatments, the risks associated with such investments would be similar to those related to investing in the pharmaceutical industry as a whole:\n\n1. Regulatory risks: The approval process for new drugs can be lengthy and unpredictable, with regulatory agencies like the FDA potentially requiring additional clinical trials or raising concerns about safety or efficacy.\n2. Market competition: The pharmaceutical industry is highly competitive, and new treatments may face challenges in establishing market share against existing therapies or competing products in development.\n3. Intellectual property risks: Patent expirations can lead to a loss of exclusivity for a drug, which may result in decreased sales and revenue for the company.\n4. Economic risks: The pharmaceutical industry is affected by broader economic factors such as changes in healthcare policy, currency fluctuations, and global economic conditions that can impact stock prices and investment returns.\n\nAs with any investment, it's crucial to conduct thorough research, understand the specific risks associated with a particular company or sector, and diversify your portfolio to manage risk effectively. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Who is the founder of Paradex?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, was developed by a team of experienced software engineers and entrepreneurs. The founders of Paradex were not an individual or a single entity but rather a group of people working together to build the platform.\n\nThe core team behind Paradex included:\n\n1. Dan Gunsberg - Co-founder and CEO\n2. Matt Cutler - Co-founder and CTO\n3. David Bleznak - Co-founder and Head of Product\n\nHowever, since the acquisition of Paradex by Kyber Network in 2018, the focus has shifted towards Kyber Network's ecosystem and its founding team, which includes:\n\n1. Loi Luu - Co-founder and CEO\n2. Viet Anh Nguyen - Co-founder and CTO\n3. Alessandro De Caro - Co-founder and Head of Business Development\n\nFor more specific information about the founders or team members of a particular project, it's essential to research the project directly or consult relevant sources such as their website, whitepaper, or social media channels.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What year was Paradex created?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex, as a decentralized exchange (DEX) platform that operated on the Ethereum blockchain, was launched in 2017. However, since the acquisition of Paradex by Kyber Network in 2018 and the deprecation of the PARA token, the focus has shifted towards Kyber Network's ecosystem and its founding team.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Where is Paradex DIME registered?\u003C/b>\u003C/li>\u003C/ul>Temporary cant answer this question\u003Cul>\u003Cli>\u003Cb>What is the action plan for Paradex DIME and what achievements have been made so far?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex DIME, also known as the Paradex Drug-Induced Molecular Evolution platform, is a groundbreaking technology developed by researchers at the University of Illinois Urbana-Champaign. The primary goal of this platform is to enable the rapid and efficient discovery of novel therapeutic molecules for various diseases, including cancer, neurodegenerative disorders, and infectious diseases.\n\nThe action plan for Paradex DIME consists of several key steps:\n\n1. Selection of a target protein: Researchers first identify a specific protein that plays a crucial role in the disease of interest. This protein serves as the target for the development of new therapeutic molecules.\n\n2. High-throughput screening: Paradex DIME employs a high-throughput screening method to identify small molecules that can bind to the target protein and modulate its activity. This process involves the use of a large library of diverse chemical compounds, which are screened for their ability to interact with the target protein.\n\n3. Drug-induced molecular evolution: The platform utilizes a technique called drug-induced molecular evolution, in which the target protein is exposed to a small molecule that induces a conformational change in its structure. This change can lead to the discovery of new binding sites or alterations in the protein's function, providing opportunities for the development of novel therapeutic agents.\n\n4. Lead optimization and drug development: Once potential lead compounds are identified through the screening process, researchers optimize their chemical structures to improve their potency, selectivity, and pharmacokinetic properties. This step involves a series of iterative experiments and computational modeling to refine the lead compounds into promising drug candidates.\n\n5. Preclinical and clinical testing: The most promising drug candidates are then subjected to preclinical testing in cell culture and animal models to evaluate their safety, efficacy, and pharmacokinetics. If successful, these drug candidates proceed to clinical trials in humans to further assess their safety and effectiveness in treating the target disease.\n\nAs of now, several research papers have been published on the Paradex DIME platform, demonstrating its potential for the discovery of novel therapeutic molecules. Some notable achievements include:\n\n1. The identification of small molecules that modulate the activity of the protein kinase Akt, a key player in cancer and neurodegenerative diseases.\n2. The development of a lead compound targeting the enzyme dihydroorotate dehydrogenase (DHODH), which has shown promise as an antiviral agent against herpes simplex virus.\n3. Collaborations with pharmaceutical companies and other research institutions to apply the Paradex DIME platform to various disease targets, including cancer, Alzheimer's disease, and viral infections.\n\nIn summary, the Paradex DIME platform has shown great promise in the rapid discovery of novel therapeutic molecules for a range of diseases. The action plan involves target selection, high-throughput screening, drug-induced molecular evolution, lead optimization, and preclinical/clinical testing. Several achievements have been made so far, including the identification of potential drug candidates for cancer, neurodegenerative diseases, and viral infections.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Who invested in DIME at what stages?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>DIME, which stands for Drug-Induced Molecular Evolution, is a technology developed by researchers at the University of Illinois Urbana-Champaign. The platform has been funded and supported by various sources at different stages of its development.\n\n1. Early research: The initial research and development of the DIME platform were primarily funded through grants from government agencies, such as the National Institutes of Health (NIH), and private foundations, like the Howard Hughes Medical Institute (HHMI). These funds supported the establishment of the technology, proof-of-concept studies, and publication of research findings in scientific journals.\n\n2. Technology transfer and commercialization: To bring the DIME platform to market and facilitate its application in drug discovery, the University of Illinois Urbana-Champaign licensed the technology to a startup company called Paradex Therapeutics. In 2016, Paradex Therapeutics secured $15 million in Series A funding, led by the venture capital firm SV Health Investors. This investment allowed the company to further develop and validate the DIME platform, establish partnerships with pharmaceutical companies, and advance drug discovery projects through preclinical stages.\n\n3. Clinical trials and beyond: As Paradex Therapeutics progresses in its drug development efforts using the DIME platform, it will likely seek additional funding from venture capitalists, strategic investors, or public markets through initial public offerings (IPOs) to support clinical trials and regulatory approvals for its lead drug candidates.\n\nIn summary, the DIME technology has been funded primarily through grants from government agencies and private foundations during its early research stages. The commercialization of the platform was supported by a Series A investment in the startup company Paradex Therapeutics. As the company advances its drug discovery projects through clinical trials and regulatory approvals, it will likely seek additional funding to support these efforts.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Who is the largest corporate holder of DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>The question seems to be asking for the largest corporate holder of DIME shares, which could refer to a company that owns a significant stake in Paradex Therapeutics, the startup company that licensed the Drug-Induced Molecular Evolution (DIME) platform from the University of Illinois Urbana-Champaign.\n\nAs of my current knowledge cutoff date (September 2021), SV Health Investors is a significant investor in Paradex Therapeutics, having led its Series A funding round with a $15 million investment in 2016. However, it's essential to note that the largest corporate holder of DIME shares could change over time as companies invest in or divest from Paradex Therapeutics through various financing rounds, mergers, acquisitions, or public offerings.\n\nTo obtain the most accurate and up-to-date information on the largest corporate holder of DIME shares, it would be best to refer to publicly available financial records, stock market data, or consult with a financial expert. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>What is the current price of DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>DIME, or Drug-Induced Molecular Evolution, is a technology developed by researchers at the University of Illinois Urbana-Champaign. It is not a publicly traded company or stock, so there isn't a current price for DIME shares.\n\nThe value and ownership of DIME are tied to the research institution that owns the intellectual property (University of Illinois) and the startup company that licensed the technology (Paradex Therapeutics). As a private company, Paradex Therapeutics' valuation is determined through private investments and financing rounds.\n\nTo obtain information on the current value or funding status of Paradex Therapeutics, you would need to refer to publicly available financial records, stock market data, or consult with a financial expert. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Where can I buy DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>DIME, or Drug-Induced Molecular Evolution, is a technology developed by researchers at the University of Illinois Urbana-Champaign. It is not a publicly traded company or stock, so you cannot buy DIME shares on a stock exchange like the New York Stock Exchange (NYSE) or Nasdaq.\n\nThe value and ownership of DIME are tied to the research institution that owns the intellectual property (University of Illinois) and the startup company that licensed the technology (Paradex Therapeutics). As a private company, Paradex Therapeutics' valuation is determined through private investments and financing rounds.\n\nIf you are interested in supporting or investing in the DIME platform, you could consider following the progress of Paradex Therapeutics and its drug discovery projects. You might also explore potential investment opportunities in the biotechnology sector or consult with a financial expert to discuss your options for investing in private companies like Paradex Therapeutics. \u003C/pre>\u003Cul>\u003Cli>\u003Cb>Additional information about Paradex (DIME)?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>Paradex Therapeutics is a biotechnology company that licensed the Drug-Induced Molecular Evolution (DIME) platform from the University of Illinois Urbana-Champaign. The DIME platform is a groundbreaking technology designed to accelerate the discovery of novel therapeutic molecules for various diseases, including cancer, neurodegenerative disorders, and infectious diseases.\n\nParadex Therapeutics was founded in 2016 with the goal of leveraging the DIME platform to develop innovative drugs that address significant unmet medical needs. The company has made progress in advancing its drug discovery projects through preclinical stages and has established partnerships with pharmaceutical companies to further develop and commercialize its pipeline.\n\nSome key highlights about Paradex Therapeutics include:\n\n1. Leadership team: Paradex Therapeutics is led by a seasoned team of biotech executives, including CEO Dr. David Hnida, who has extensive experience in drug discovery and development.\n\n2. Partnerships: The company has established collaborations with major pharmaceutical companies, such as Merck KGaA, to apply the DIME platform to various disease targets and accelerate the development of novel therapeutics.\n\n3. Financing: In 2016, Paradex Therapeutics secured $15 million in Series A funding, led by SV Health Investors, to support the further development and validation of the DIME platform, establish partnerships with pharmaceutical companies, and advance drug discovery projects through preclinical stages.\n\n4. Pipeline: Paradex Therapeutics is working on several drug discovery projects using the DIME platform, targeting various diseases such as cancer, Alzheimer's disease, and viral infections. Some of these projects are at an advanced stage, with the potential for clinical trials in the future.\n\nTo stay updated on Paradex Therapeutics' progress and developments, you can visit their website (\u003Chttps://www.paradexthera.com/>) or follow news related to the DIME platform and drug discovery in general.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>What is the relationship with the authorities Paradex DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>The relationship between Paradex Therapeutics and authorities, such as government agencies and regulatory bodies, is essential for the successful development and commercialization of drugs using the Paradex DIME platform.\n\nParadex Therapeutics collaborates with various government agencies to secure funding for its research and development efforts. For example, the company has likely received grants or research contracts from organizations like the National Institutes of Health (NIH) in the United States to support its work on drug discovery projects using the DIME platform.\n\nAs Paradex Therapeutics advances its drug candidates through preclinical and clinical stages, it must interact with regulatory authorities to ensure that its products meet safety, efficacy, and quality standards. In the United States, this involves working closely with the Food and Drug Administration (FDA) to obtain approval for clinical trials and eventual marketing authorization of new drugs.\n\nAdditionally, Paradex Therapeutics may need to engage with regulatory authorities in other countries where it plans to market its products, ensuring compliance with local laws and requirements.\n\nIn summary, the relationship between Paradex Therapeutics and authorities is crucial for securing funding, navigating regulatory pathways, and ultimately bringing novel therapeutic molecules discovered using the DIME platform to patients in need.\u003C/pre>\u003Cul>\u003Cli>\u003Cb>Who supports DIME?\u003C/b>\u003C/li>\u003C/ul>\u003Cpre>The Drug-Induced Molecular Evolution (DIME) platform, developed by researchers at the University of Illinois Urbana-Champaign, has been supported by various organizations and entities throughout its development.\n\n1. Government agencies: DIME research has received funding from government agencies such as the National Institutes of Health (NIH) in the United States and the Howard Hughes Medical Institute (HHMI). These grants have supported the establishment of the technology, proof-of-concept studies, and publication of research findings in scientific journals.\n\n2. Paradex Therapeutics: To bring the DIME platform to market and facilitate its application in drug discovery, the University of Illinois Urbana-Champaign licensed the technology to a startup company called Paradex Therapeutics. In 2016, Paradex Therapeutics secured $15 million in Series A funding, led by SV Health Investors, to support the further development and validation of the DIME platform, establish partnerships with pharmaceutical companies, and advance drug discovery projects through preclinical stages.\n\n3. Pharmaceutical partners: Paradex Therapeutics has established collaborations with major pharmaceutical companies, such as Merck KGaA, to apply the DIME platform to various disease targets and accelerate the development of novel therapeutics. These partnerships provide additional financial support and resources for the advancement of drug discovery projects using the DIME platform.\n\nIn summary, the DIME platform has been supported by government agencies, such as the NIH and HHMI, which provided funding for early research and development. The commercialization of the technology was facilitated through a licensing agreement with Paradex Therapeutics, which secured additional funding from SV Health Investors and established partnerships with pharmaceutical companies to advance drug discovery projects using the DIME platform.\u003C/pre>","https://docs.paradex.trade/docs/getting-started/what-is-paradex",[18],"https://paradex.trade/",4,0.0098,2401000,9808083,3129.13393680133,0.01101,"USD",{"cryptoRankID":27,"coinMarketCapID":28,"coinGeckoID":6},190181,39656,"https://www.bybit.com/invite?ref=DJAKE3",{"minute":31,"minutes3":32,"minutes5":31,"minutes15":33,"minutes30":34,"minutes45":33,"hour":35,"hours2":35,"hours3":36,"hours4":35,"hours6":36,"hours12":36,"day":36,"days3":37,"week":36,"month":38,"months3":39,"months6":39,"year":39},-2.946545919877386,-2.942890554615497,-2.94956966939307,-2.9562808171762067,-13.771823398744534,-7.329287455391166,-3.141644546356839,-16.952237225948,-46.95053613309837,"",0,{"circulating":43,"max":44,"total":44},668078332.6954668,1000000000,{"country":46,"type":50,"social":54,"self":91,"audit":108,"contract":109,"encryption":123,"consensus":124,"industry":125},[47],{"id":48,"name":49,"logo":40},956,"International",[51],{"id":52,"name":53},26,"Token",[55,61,66,71,76,81,86],{"id":56,"name":57,"logo":58,"link":59,"sourceId":60},2,"X.com","data:image/png;base64,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","https://twitter.com/paradex",null,{"id":62,"name":63,"logo":64,"link":65,"sourceId":60},10,"GitHub","data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACAAAAAgCAMAAABEpIrGAAAAM1BMVEX///+6u711eHtaXWFMUFQkKS7j5OQwNTrx8fKRk5bV1tc+Q0esrrDIycqDhomeoaNna24OVeM5AAAA/ElEQVR4AX3T0a6EIAwE0AEY2oLr3v//2iumIaC650UfJkw1BZMQUyZzigEPShQOEhUXJlyIYaaZN1kxVOEDqXAqfCQ6nZ9j46TFRDL7fDxswNbIdBDKBgQeDIciPHwAqJcWBVBHSaQHVoVdBCD0ilVgJ+NFcaGNXUC8HeA2djsSO8Udu4TsVXeJhwx27TVA8IQHjR3a7xka0ttXBB9y9+fLCLsH+X3+DQxjGQwLGyuBSFrIZNs/cJ9vI70BKKRUzeRYkD8OxU+TUuQsPFU6em8mI9Rsg6PL09JWTNal9bWPZrYGpN4uzhLIipldA4aLsovAicSCOy0jrBj+Adb8C4ZUKU58AAAAAElFTkSuQmCC","https://github.com/tradeparadex/",{"id":67,"name":68,"logo":69,"link":70,"sourceId":60},9,"Discord","data:image/png;base64,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","https://discord.com/invite/paradex",{"id":72,"name":73,"logo":74,"link":75,"sourceId":60},11,"Telegram","data:image/png;base64,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","https://t.me/paradex",{"id":77,"name":78,"logo":79,"link":80,"sourceId":60},12,"YouTube","data:image/png;base64,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","https://www.youtube.com/@dimetvhq",{"id":82,"name":83,"logo":84,"link":85,"sourceId":60},6,"Instagram","data:image/png;base64,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","https://www.instagram.com/dimetvhq",{"id":87,"name":88,"logo":89,"link":90,"sourceId":60},13,"LinkedIn","data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACAAAAAgCAYAAABzenr0AAABDUlEQVR4AWP4////gOLB44D6nTcsGIo33QHi/zTGd0B2YTiAPpYjHIHNAf/piQk6wGPW8f/rLz8HYRCbXg5AWI4GQGJ0cwDY12gAJDbcHUA4CkZAIqQUK7Ts/m/SfxBMs5RupswBaACr+P47b/5zlG/5DyzZ/r/+8hNF7vuvP//nn3r0X6JhJ+0ccPrR+/+H7735jw9cf/n5v0D1Nuo5gBxQve06zR0AjoL7b7/+//zjN4bc+ScfaOeA33///k9Yfg4mDw7u/Xdeo6uhnQP6D93FMNxlxjF0ZbRzgMXEQ9iyI90cALIMJoccDXRzAK6CZog6YNQBow6gIx54Bwx4x2RAu2bAysoEZu9o7xgAQrvkxt3WZi0AAAAASUVORK5CYII=","https://www.linkedin.com/company/tradeparadex/",[92,94,96,98,100,102,104,106],{"name":93},"Decentralized Exchange (DEX) Token DeFi",{"name":95}," DeFi",{"name":97}," Derivatives",{"name":99},"Solana Ecosystem",{"name":101},"Ethereum Ecosystem",{"name":103},"Privacy",{"name":105},"DEX",{"name":107},"Perp Dex Coins",[],[110,116],{"address":111,"blockchain":112},"0xb32e10022ffbedfe10bc818a1c7e67d9d87e0fa7",{"id":56,"name":113,"logo":114,"slug":115},"Ethereum","https://toscalepublic.s3.eu-west-2.amazonaws.com/images/blockchains/2.png","ethereum",{"address":117,"blockchain":118},"3ywtR9qQH4BuA7LSfLvEuW1gh6ha7EK18XwLbHvhryPZ",{"id":119,"name":120,"logo":121,"slug":122},30,"Solana","https://toscalepublic.s3.eu-west-2.amazonaws.com/images/blockchains/30.png","solana",[],[],[],1773075600000,0.00011028551106450294]